Anticorps Monoclonal anti-SPARC

SPARC Monoclonal Antibody for WB, IHC, IF/ICC, Indirect ELISA

Hôte / Isotype

Mouse / IgG2a

Réactivité testée

Humain

Applications

WB, IHC, IF/ICC, Indirect ELISA

Conjugaison

Non conjugué

CloneNo.

1A2C1

N° de cat : 66426-1-PBS

Synonymes

Basement membrane protein 40, BM 40, ON, Osteonectin, SPARC



Informations sur le produit

66426-1-PBS cible SPARC dans les applications de WB, IHC, IF/ICC, Indirect ELISA et montre une réactivité avec des échantillons Humain

Réactivité Humain
Hôte / Isotype Mouse / IgG2a
Clonalité Monoclonal
Type Anticorps
Immunogène SPARC Protéine recombinante Ag7390
Nom complet secreted protein, acidic, cysteine-rich (osteonectin)
Masse moléculaire calculée 35 kDa
Poids moléculaire observé 38 kDa, 52 kDa
Numéro d’acquisition GenBankBC004974
Symbole du gène SPARC
Identification du gène (NCBI) 6678
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Purification par protéine A
Tampon de stockage PBS only
Conditions de stockageStore at -80°C. 20ul contiennent 0,1% de BSA.

Informations générales

SPARC, also known as ON (Osteonectin) or BM-40 (Basement-membrane protein 40), is an extracellular glycoprotein with the calculated molecular mass of 35 kDa and the apparent molecular mass of 40-43 kDa and 50 kDa (PMID: 7495300, 12365801). SPARC belongs to a group of matricellular proteins defined as secreted components that do not contribute directly to the formation of structural elements but serve to modulate cell-matrix interactions and cellular functions (PMID: 7542656; 12231357). SPARC is expressed at high levels in bone tissue, is distributed widely in many other tissues and cell types, and is associated generally with tissues undergoing morphogenesis, remodeling and wound repair (PMID: 10567433). It elicits changes in cell shape, inhibits cell-cycle progression, and influences the synthesis of extracellular matrix (PMID: 12721366). Altered expression of SPARC has been reported in a variety of cancers, which include breast, ovarian, colorectal, and pancreatic cancer as well as melanoma and glioblastomas (PMID: 18849185).

{{ptg:RelatedPrimaryAntibodies}}